OM

+ Watchlist + Portfolio

Outset Medical, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $4.30
52-Week Range: $3.00 – $16.16
Market Cap: $80.83M
P/E (TTM): —
EPS (TTM): -3.80
Dividend Yield: —

Advanced Metrics

Price/Book: 0.62
PEG Ratio: —
Return on Equity: -59.17%
Return on Assets: -15.54%
Gross Margin: 41.76%
Operating Margin: -49.55%
Profit Margin: -63.06%
Current Ratio: 5.19
Debt/Equity: 1.08
Total Debt: $104.45M
Free Cash Flow: $-14.68M
Revenue Growth: 0.70%
Earnings Growth: —
Enterprise Value: $38.08M

OM Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$115.38M	$130.38M	$113.69M	$119.48M
Cost of Revenue	$97.54M	$101.38M	$75.13M	$72.72M
Gross Profit	$17.83M	$29.00M	$38.56M	$46.75M
Research & Development	$48.85M	$57.31M	$38.40M	$21.23M
Selling, General & Admin	$130.00M	$141.46M	$113.54M	$92.22M
Operating Expenses	$178.85M	$198.77M	$151.94M	$113.46M
Operating Income	-$161.02M	-$169.77M	-$113.38M	-$66.71M
EBITDA	-$153.93M	-$153.79M	-$97.89M	-$62.64M
Pretax Income	-$162.66M	-$172.27M	-$127.48M	-$80.94M
Income Tax	$295.00K	$523.00K	$491.00K	$718.00K
Net Income	-$162.96M	-$172.80M	-$127.98M	-$81.65M
Diluted EPS	-50.70	-52.20	-36.90	-5.37
Diluted Shares	3.21M	3.31M	3.46M	15.21M

OM Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$73.22M	$68.51M	$124.01M	$35.01M
Receivables	$28.07M	$32.98M	$35.62M	$28.33M
Inventory	$51.48M	$49.22M	$59.39M	$47.61M
Current Assets	$373.64M	$291.22M	$258.22M	$250.88M
Total Assets	$400.12M	$313.80M	$275.80M	$264.50M
Current Liabilities	$51.95M	$55.32M	$45.38M	$37.63M
Long-Term Debt	$96.34M	$130.11M	$197.38M	$96.24M
Total Debt	$103.23M	$136.19M	$201.86M	$101.25M
Total Liabilities	$154.13M	$190.91M	$248.98M	$137.54M
Retained Earnings	-$788.95M	-$961.75M	-$1.09B	-$1.17B
Shareholders' Equity	$245.99M	$122.89M	$26.82M	$126.95M
Working Capital	$321.70M	$235.90M	$212.84M	$213.25M
Net Debt	$23.11M	$61.60M	$73.36M	$61.23M

OM Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$145.73M	-$131.37M	-$116.30M	-$46.33M
Capital Expenditure	-$8.32M	-$3.44M	-$912.00K	-$798.00K
Free Cash Flow	-$154.05M	-$134.81M	-$117.22M	-$47.13M
Depreciation & Amortisation	$5.17M	$5.81M	$5.73M	$4.34M
Stock-Based Compensation	$27.20M	$38.63M	$29.36M	$15.62M
Investing Cash Flow	-$66.30M	$83.03M	$103.94M	-$97.68M
Financing Cash Flow	$72.90M	$43.65M	$67.87M	$55.50M
Net Change in Cash	-$139.13M	-$4.70M	$55.51M	-$88.51M

OM Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$29.75M	$31.42M	$29.43M	$28.87M	$27.86M
Cost of Revenue	$18.69M	$19.55M	$17.84M	$16.64M	$15.77M
Gross Profit	$11.07M	$11.87M	$11.59M	$12.23M	$12.10M
Research & Development	$5.51M	$5.29M	$5.38M	$5.05M	$5.62M
Selling, General & Admin	$21.95M	$23.44M	$22.03M	$24.80M	$23.40M
Operating Expenses	$27.46M	$28.73M	$27.40M	$29.86M	$29.01M
Operating Income	-$16.40M	-$16.86M	-$15.81M	-$17.63M	-$16.92M
EBITDA	-$20.81M	-$13.81M	-$12.95M	-$15.07M	-$14.60M
Pretax Income	-$25.67M	-$18.44M	-$17.43M	-$19.40M	-$18.76M
Income Tax	$115.00K	$104.00K	$404.00K	$95.00K	$217.00K
Net Income	-$25.78M	-$18.54M	-$17.84M	-$19.49M	-$18.98M
Diluted EPS	-3.66	-1.04	-1.00	-1.09	-1.03
Diluted Shares	7.04M	17.74M	17.78M	17.82M	18.37M

OM Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$75.93M	$39.56M	$36.44M	$35.01M	$30.56M
Receivables	$36.89M	$34.89M	$32.96M	$28.33M	$25.32M
Inventory	$55.77M	$52.25M	$49.29M	$47.61M	$49.65M
Current Assets	$286.56M	$275.58M	$265.37M	$250.88M	$236.71M
Total Assets	$301.21M	$288.80M	$277.25M	$264.50M	$249.45M
Current Liabilities	$34.22M	$36.91M	$37.45M	$37.63M	$37.61M
Long-Term Debt	$94.11M	$94.81M	$95.52M	$96.24M	$96.94M
Total Debt	$98.17M	$98.43M	$98.68M	$101.25M	$101.61M
Total Liabilities	$131.34M	$134.02M	$134.89M	$137.54M	$137.77M
Retained Earnings	-$1.12B	-$1.13B	-$1.15B	-$1.17B	-$1.19B
Shareholders' Equity	$169.87M	$154.78M	$142.37M	$126.95M	$111.69M
Working Capital	$252.34M	$238.67M	$227.92M	$213.25M	$199.10M
Net Debt	$18.19M	$55.26M	$59.09M	$61.23M	$66.38M

OM Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$25.66M	-$4.82M	-$6.32M	-$9.52M	-$12.84M
Capital Expenditure	-$123.00K	-$292.00K	-$160.00K	-$223.00K	-$65.00K
Free Cash Flow	-$25.79M	-$5.12M	-$6.48M	-$9.74M	-$12.91M
Depreciation & Amortisation	$1.29M	$1.16M	$1.01M	$881.00K	$795.00K
Stock-Based Compensation	$2.98M	$3.50M	$5.08M	$4.06M	$3.45M
Investing Cash Flow	-$78.08M	-$31.16M	$2.97M	$8.59M	$7.90M
Financing Cash Flow	$55.66M	-$384.00K	$231.00K	$0.00	$501.00K
Net Change in Cash	-$48.09M	-$36.37M	-$3.12M	-$931.00K	-$4.44M

Market Snapshot

About

Outset Medical manufactures dialysis machines designed for ease of use and flexibility. The company's Tablo Hemodialysis System allows dialysis treatment in various settings including home, acute care hospitals, and dialysis centers. Outset aims to expand access to kidney care by simplifying the dialysis process.